Open Access<p>A rare case of acute promyelocytic leukemia with IRF2BP2-RARA fusion; and literature review</p>
Author(s) -
Yiping Liu,
Fang Xu,
Hong Hu,
Junping Wen,
Jing Su,
Qin Zhou,
Wen Qu
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s217622
Subject(s) - acute promyelocytic leukemia , arsenic trioxide , medicine , neuroblastoma ras viral oncogene homolog , cancer research , retinoic acid , leukemia , hematopoietic stem cell transplantation , oncology , transplantation , biology , cancer , cell culture , kras , genetics , colorectal cancer , apoptosis
Acute promyelocytic leukemia (APL) is commonly characterized by the fusion of retinoic acid receptor alpha (RARA) with promyelocytic leukemia (PML). Most APL patients acquire long-term survival after treatment with all-trans retinoic acid (ATRA) or arsenic agents-based chemotherapy.